{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:09:06Z","timestamp":1789168146259,"version":"build-2803163510"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lenacapavir (LEN) with an optimized background regimen (OBR) was evaluated in a French cohort of participants with multidrug-resistant human immunodeficiency virus (HIV) via compassionate use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults (n = 42) with HIV-1 (PLWH1, n = 33) or HIV-2 (PLWH2, n = 9), receiving at least 1 dose of LEN plus OBR, were prospectively followed between January 2021 and December 2023. The primary endpoint was virological suppression (plasma HIV-1 RNA [VL] &amp;lt;50\u2005copies\/mL at week 26 (W26)) or maintenance, using the US Food and Drug Administration Snapshot algorithm. Secondary endpoints included long-term VL, resistance emergence, LEN plasma concentration, and drug safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, PLWH1 presented with a median VL of 4.0\u2005log10 copies\/mL with 14 of 33 (42%) having VL &amp;lt;50\u2005copies\/mL, while PLWH2 had 3.0\u2005log10 copies\/mL (with baseline VL &amp;lt;50\u2005copies\/mL for 3). By W26, virological suppression was achieved or maintained in 67.0% (95% CI, 48.2%\u201382.0%) of PLWH1, with a mean CD4+ increase of +86\u2005cells\/\u03bcL. In PLWH2, virological suppression occurred in only 22.0% (95% CI, 2.8%\u201360.0%), with CD4+ counts rising by +27\u2005cells\/\u03bcL. Emergence of LEN resistance was documented in 1 PLWH1 (Q67H) and 3 PLWH2 (all N73D). The median (IQR) LEN plasma concentration was 43\u2005(31&amp;ndashng\/mL after 26 weeks of subcutaneous injections. Tolerance was acceptable with 31% reported injection site reactions leading to discontinuation in 2 patients, and no grade 3\/4 treatment-related adverse events occurred (2 deaths unrelated to treatment).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LEN plus OBR showed robust efficacy and safety in PLWH1 but limited antiviral activity in PLWH2 due to limited OBR. These findings support LEN as an effective option in highly treatment-experienced PLWH1, while underscoring challenges for PLWH2.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag353","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:50:53Z","timestamp":1780487453000},"source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and Safety of Lenacapavir-Containing Regimens in Highly Experienced HIV-Infected Patients With Multidrug Resistance: Real-world Results From the French Compassionate Use Program"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6081-7993","authenticated-orcid":false,"given":"Constance","family":"Delaugerre","sequence":"first","affiliation":[{"name":"Service de Virologie, AP-HP, H\u00f4pital Saint Louis, Universit\u00e9 Paris Cit\u00e9, INSERM IRSL UMR1342 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mafi","sequence":"additional","affiliation":[{"name":"Service de Virologie, AP-HP, H\u00f4pital Saint Louis, Universit\u00e9 Paris Cit\u00e9, INSERM IRSL UMR1342 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arbnor","family":"Zenuni","sequence":"additional","affiliation":[{"name":"Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, INSERM, Universit\u00e9 Sorbonne , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-537X","authenticated-orcid":false,"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Amat","sequence":"additional","affiliation":[{"name":"Institut de M\u00e9decine et d\u2019Epid\u00e9miologie Appliqu\u00e9e, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Seang","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Necker , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chirio","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, H\u00f4pital l\u2019Archet 1, CHU de Nice, Universit\u00e9 C\u00f4te d\u2019Azur , Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Viard","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital H\u00f4tel-Dieu , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Hocqueloux","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, H\u00f4pital Universitaire d\u2019Orl\u00e9ans, LI2RSO Universit\u00e9 d\u2019Orl\u00e9ans , Orl\u00e9ans ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Estrabaud","sequence":"additional","affiliation":[{"name":"Gilead Sciences Medical Affairs France, , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Bichat-Claude Bernard, INSERM IAME, Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Landman","sequence":"additional","affiliation":[{"name":"Institut de M\u00e9decine et d\u2019Epid\u00e9miologie Appliqu\u00e9e, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]},{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Bichat-Claude Bernard, INSERM IAME, Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Assoumou","sequence":"additional","affiliation":[{"name":"Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, INSERM, Universit\u00e9 Sorbonne , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"Service de Virologie, AP-HP, H\u00f4pital Bichat-Claude Bernard, INSERM IAME, Universit\u00e9 Paris Cit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[{"name":"Service de Maladies Infectieuses et Tropicales, AP-HP, H\u00f4pital Saint Antoine, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, UMR-S1136, Universit\u00e9 Sorbonne , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"2026063011222578600_ofag353-B1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"2026063011222578600_ofag353-B2","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/infdis\/jiad562","article-title":"Antiviral activity of lenacapavir against human immunodeficiency virus type 2 (HIV-2) isolates and drug-resistant HIV-2 mutants","volume":"229","author":"Smith","year":"2024","journal-title":"J Infect Dis"},{"key":"2026063011222578600_ofag353-B3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/COH.0000000000000713","article-title":"Lenacapavir: a first-in-class HIV-1 capsid inhibitor","volume":"17","author":"Dvory-Sobol","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"2026063011222578600_ofag353-B4","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1021\/acs.molpharmaceut.3c00626","article-title":"Lenacapavir: a novel, potent, and selective first-in-class inhibitor of HIV-1 capsid function exhibits optimal pharmacokinetic properties for a long-acting injectable antiretroviral agent","volume":"20","author":"Subramanian","year":"2023","journal-title":"Mol Pharm"},{"key":"2026063011222578600_ofag353-B5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N Engl J Med"},{"key":"2026063011222578600_ofag353-B6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/00002030-200106150-00015","article-title":"Non-adherence to highly active antiretroviral therapy predicts progression to AIDS","volume":"15","author":"Bangsberg","year":"2001","journal-title":"AIDS"},{"key":"2026063011222578600_ofag353-B7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/17512433.2018.1453805","article-title":"Treatment and prevention of HIV infection with long-acting antiretrovirals","volume":"11","author":"Ben\u00edtez-Guti\u00e9rrez","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026063011222578600_ofag353-B8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-med-041217-013717","article-title":"Long-acting HIV drugs for treatment and prevention","volume":"70","author":"Gulick","year":"2019","journal-title":"Annu Rev Med"},{"key":"2026063011222578600_ofag353-B9","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"2026063011222578600_ofag353-B10","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/S2352-3018(23)00113-3","article-title":"Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2\/3 trial","volume":"10","author":"Ogbuagu","year":"2023","journal-title":"Lancet HIV"},{"key":"2026063011222578600_ofag353-B11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/cid\/ciae423","article-title":"Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multidrug-resistant HIV-1: week 104 results of a phase 2\/3 trial","volume":"80","author":"Ogbuagu","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026063011222578600_ofag353-B12","doi-asserted-by":"crossref","first-page":"ofaf763","DOI":"10.1093\/ofid\/ofaf763","article-title":"Subcutaneous lenacapavir in people with multidrug-resistant HIV-1: 156 week results of the CAPELLA study","volume":"13","author":"Ogbuagu","year":"2026","journal-title":"Open Forum Infect Dis"},{"key":"2026063011222578600_ofag353-B13","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/infdis\/jiac364","article-title":"Resistance analyses in highly treatment-experienced people with human immunodeficiency virus (HIV) treated with the novel capsid HIV inhibitor lenacapavir","volume":"226","author":"Margot","year":"2022","journal-title":"J Infect Dis"},{"key":"2026063011222578600_ofag353-B14","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/jiaf050","article-title":"Resistance analyses in heavily treatment-experienced people with HIV treated with the novel HIV capsid inhibitor lenacapavir after 2 years","volume":"231","author":"Margot","year":"2025","journal-title":"J Infect Dis"},{"key":"2026063011222578600_ofag353-B15","first-page":"457","article-title":"2025 update of the drug resistance mutations in HIV-1","volume":"33","author":"Wensing","year":"2025","journal-title":"Top Antivir Med"},{"key":"2026063011222578600_ofag353-B16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cid\/ciae650","article-title":"Rapid selection of HIV-2 capsid mutations in salvage therapy with lenacapavir-containing regimen","volume":"81","author":"Montrouge","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026063011222578600_ofag353-B17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1684\/vir.2019.0789","article-title":"Physiopathology of HIV-2 infection","volume":"23","author":"Visseaux","year":"2019","journal-title":"Virologie (Montrouge)"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag353\/68528685\/ofag353.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag353\/68528685\/ofag353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag353\/68528685\/ofag353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:16:00Z","timestamp":1782886560000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag353\/8708195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag353","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"ofag353"}}